JCLA:百草枯中毒患者血浆凝血酶原时间延长与预后不良有关

2019-01-18 MedSci MedSci原创

口服百草枯入血后可严重损伤血管内皮细胞,引起凝血功能障碍。在本研究中,研究人员的目的是寻找一种常规凝血指标,作为急性百草枯中毒患者预后的指标。 2012年1月~ 2016年12月,研究人员对209例口服百草枯自杀未遂收治患者开展研究。常规凝血指标包括血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fbg)、凝血酶时间(TT)、D二聚体,分析其变化趋势及其与预后的关系。

口服百草枯入血后可严重损伤血管内皮细胞,引起凝血功能障碍。在本研究中,研究人员的目的是寻找一种常规凝血指标,作为急性百草枯中毒患者预后的指标。

20121~ 201612月,研究人员对209例口服百草枯自杀未遂收治患者开展研究。常规凝血指标包括血浆凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fbg)、凝血酶时间(TT)D二聚体,分析其变化趋势及其与预后的关系。

结果显示,30 mLPTAPTT值均显著高于<30 mL(P< .01)。入院1周内PTAPTT值逐渐降低,Fbg水平逐渐升高。单因素和多因素Cox回归分析表明,性别、摄食量和PT40天内死亡率的独立预测因素。PT <12秒患者与PT 12秒患者的累计生存率差异显著(P = 0.001)

研究结果表明,百草枯中毒患者凝血状态与预后密切相关。常规监测凝血功能,尤其是血浆PT,有助于分析PQ中毒患者的病情和预后。

原始出处:

Xiao Hu, Renyong Guo, Xing Chen, Yu Chen Increased plasma prothrombin time is associated with poor prognosis in patients with paraquat poisoning

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1319105, encodeId=15c11319105d3, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399119, encodeId=e9441399119db, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415957, encodeId=0d18141595edb, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488351, encodeId=96541488351d9, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 mashirong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1319105, encodeId=15c11319105d3, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399119, encodeId=e9441399119db, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415957, encodeId=0d18141595edb, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488351, encodeId=96541488351d9, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1319105, encodeId=15c11319105d3, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399119, encodeId=e9441399119db, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415957, encodeId=0d18141595edb, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488351, encodeId=96541488351d9, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1319105, encodeId=15c11319105d3, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1399119, encodeId=e9441399119db, content=<a href='/topic/show?id=1812e18986d' target=_blank style='color:#2F92EE;'>#百草枯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71898, encryptionId=1812e18986d, topicName=百草枯)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19562191272, createdName=xxxx1050, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415957, encodeId=0d18141595edb, content=<a href='/topic/show?id=6e0631341b6' target=_blank style='color:#2F92EE;'>#凝血酶原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31341, encryptionId=6e0631341b6, topicName=凝血酶原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15d23117049, createdName=gostraight, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488351, encodeId=96541488351d9, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Sun Jan 20 04:18:00 CST 2019, time=2019-01-20, status=1, ipAttribution=)]

相关资讯

Int J Oral Max Surg:口腔鳞状细胞癌患者唾液和血浆中细胞因子生物标志物

这项研究的目的是调查人类唾液和血浆中潜在的生物标志物,以帮助早期诊断口腔鳞状细胞癌(OSCC)。

Diabetologia:瑞典人群中与2型糖尿病相关的血浆代谢物

近日,国际杂志 《Diabetologia》上在线发表一项关于瑞典人群中与2型糖尿病相关的血浆代谢物的前瞻性队列中的病例对照研究。 研究的目的是确定预测未来2型糖尿病的血浆代谢物,鉴定后来发展或未发展成2型糖尿病个体的代谢物的变化,并评估哪种代谢物在什么程度上能改善风险预测。 研究人员在瑞典基于人群的Västerbotten干预计划队列中建立了巢式病例对照研究。使用非靶向液相色谱 -

Lancet:血浆优先复苏在失血性休克患者的城区内地面转运中无优势

50多年以来,晶体复苏一直是严重创伤所致凝血功能受损的标准治疗。在2003-2005年伊拉克战争中,美军发现使用高比例的血浆对红细胞可提高存活率。随后在平民中的研究对优先使用血浆治疗能否提高存活并无定论。

J Cell Mol Med:二型糖尿病视网膜病变患者血浆中的miR-29b和miR-200b水平

巴西人类分子遗传学实验室的Dantas da Costa E Silva ME等人近日在J Cell Mol Med杂志上发表了一篇重要的工作,他们对186例巴西南部2型糖尿病患者血浆中的miR-29b和miR-200b水平进行研究,看是否与DR相关。

JAMA:美国医院红细胞及血浆输注减少

《美国医学会杂志》(JAMA)杂志发表的一项以人群为基础的最新大规模分析显示,美国医院的红细胞(RBC)及血浆输注在20多年保持稳定增长后呈现下降。

CCLM:IL8和IL16水平可显示血清和血浆质量?

较长的预先离心时间会改变血清和血浆样品的质量。目前,已经确定了样品处理过程中延迟的标记以及样品质量的标记。 本研究中,研究人员通过筛选血清,EDTA血浆和柠檬酸盐血浆样品中的二十种细胞因子在室温下由延长的血液预先离心延迟诱导的浓度变化。显示出最大变化的两种细胞因子在鉴定血清或血浆样品时具有“诊断性能”,因此进一步得到验证。 研究表明,使用R&D Systems ELISA试剂盒,EDT